NY-ESO-1 peptide 94-102 is naturally processed from the full-length protein in antigen-presenting cells. ELISPOT assay with CD8+ T cells from patient UC-098 presensitized with NY-ESO-1 peptide 80-109 and tested against histocompatible B-EBV targets pulsed with NY-ESO-1 peptides, or infected with vaccinia virus recombinant for NY-ESO-1 or wild-type (A); or tested against melanoma cell lines pulsed or not with NY-ESO-1 peptide 94-102 (B).